Second- and third-generation ALK inhibitors for non-small cell lung cancer

Table 1 FDA approved ALK inhibitors for non-small cell lung cancer

Trials	Patients	Agents	No.	ORR	PFS	P value	Refs.
Phase III PROFILE1007	Relapsed refractory	Crizotinib vs pemetrexed/docetaxel	173 174	65 % 20 %	7.7 ms 3.0 ms	<0.001	[13]
Phase III PROFILE1014	Untreated	Crizotinib vs chemotherapy	172 171	74 % 45 %	10.9 ms 7.0 ms	<0.001	[36]
Phase I	Failed chemotherapy and crizotinib	Ceritinib (NSCLC, ≥400 mg)	114	58 %	7.0 ms	N/A	[63]
Phase I/II	Failed chemotherapy and crizotinib	Alectinib (phase II)	46	94 %	NA	N/A	[67]
Phase I/II	Failed chemotherapy and crizotinib	Alectinib (phase II)	47	55 %	NA	N/A	[68]

Abbreviations: N/A not applicable, No. number, ORR overall response rate, DOR duration of response, PFS progression-free survival, Ref reference, wks weeks, ms months

ISSN: 1756-8722